Welcome to Clinical and Translational Allergy by Lötvall, Jan & Cardona, Victoria
EDITORIAL Open Access
Welcome to Clinical and Translational Allergy
Jan Lötvall
1* and Victoria Cardona
2
It is with the greatest satisfaction and pride that the
European Academy of Allergy and Clinical Immunology
(EAACI) today can launch its first open access scientific
journal, “Clinical and Translational Allergy” (CTA).
Over many years, EAACI have focused on publishing
two major journals, Allergy as well as Pediatric Allergy
and Immunology (PAI). However, these two excellent
journals alone are limited in their ability to publish a
considerable number of articles despite their quality,
and therefore are insufficient to provide the required
platform for communication of many high quality scien-
tific papers for the EAACI community. Consequently, in
the last years it has become evident that new journals
need to be established by the Academy. It was also felt
that Open Access was crucial for any new EAACI jour-
nal, as many funding bodies today require the research
to be published in this way, and open access makes pub-
lished research available to the general public, without
any need for subscriptions. A key principle for CTA will
be to provide a very rapid and fair review process for all
submission, and we hope the journal becomes a favour-
ite for your, and the allergy, asthma and immunology
community as a whole. Further, all manuscripts
accepted for publication in CTA will be immediately
published online, as the publication date is not at all
dependent on publication of a printed issue, as is the
case for print journals.
The aim of CTA is to provide a platform for the disse-
mination of original allergy-immunology research, excit-
ing reviews as well as EAACI-developed position papers.
Today, at the launch of the journal, one position paper
and three exciting reviews are published, and several
recently submitted original research papers are under
consideration. Firstly, a very long-term effort in develop-
ing an EAACI position paper on diagnostic tools in rhi-
nology is published in CTA [1]. This publication has
taken several years to develop, and is the most compre-
hensive publication on the topic to date. Three review
articles are discussing different interesting aspects and
theories in allergy. One, by Woo and Bahna [2], dis-
cusses the different types of reactions that can be
induced by shellfish ingestion, and the clinical misinter-
pretations that can evolve. Another review article, by
Chaudhary and Marr [3], considers the impact that
Aspergillus Fumigatus can have on respiratory disease.
Lastly, an overview article by Mattila and colleagues [4],
examines the role of respiratory and conjunctival epithe-
lium in airway allergic disease. These fundamentally dif-
ferent topics not only contribute to the literature, but
also illustrate the width of topics that CTA will publish.
Beyond clinical experimental research and epidemiology,
CTA will certainly also accept any studies using animal
models of any allergic process, and immunological
research related to allergic disease.
The field of allergy concerns the most common group
of diseases globally. Allergic diseases have grown rapidly
in prevalence in the industrialized world, and are now
rapidly growing in developing countries. It is considered
that diseases of the immune system, such as allergic dis-
eases, are best explained through a clear grasp of normal
immune mechanisms and the ways by which these pro-
cesses become dysfunctional. This is one of the explana-
tions of selecting the name of the journal, including the
key word “translational”, since it is likely that the most
interesting future results will evolve from truly transla-
tional research. Therefore, manuscripts describing
research that utilises several techniques to prove a key
biological process, or explaining effect of a treatment,
will receive extra attention by the journal.
Each manuscript submitted to CTA will be externally
peer reviewed, to achieve independent input on the
quality of the research, the appropriateness of any
review, and the quality of the research presented. The
written English will also need to be of very high quality
for any manuscript to be considered by the journal.
Importantly, the Editor’s decisions remain independent,
and are not only based on reviewer’sc o m m e n t sa n d
suggestions, but also on priorities made by the Editors.
The current editorial board of CTA has primarily been
recruited among leaders within the EAACI community
(http://www.ctajournal.com/about/edboard). However,
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One advantage with the open access system is the
availability of the published research online. However,
any publication process costs money, and since there is
no subscription income to open access journals, the cost
will have to be covered by the publishing authors.
Therefore, CTA will charge a nominal fee for any article
published, which will have to be covered by the authors
of the article. This is becoming a common approach for
many scientists preferably publishing in Open Access
journals, and the total cost for publishing in CTA is
lower than for subscriptions to other journals. The
nominal fee for publishing in CTA is currently £1095
(€1250). As for all BioMed Central journals, authors
from countries listed in the World Bank low or lower-
middle income bracket are automatically granted a
waiver of the publication charges, to ensure that inabil-
ity to pay is not a barrier to publication [5].
Last, but not least, CTA is established not only for the
benefit of EAACI, but for the good of the global allergy
community. Again this is well illustrated by the first
published reviews [1-4], including authors from many
parts of the world. We look forward to receiving your
submission in the not too distant future, regardless of
which continent you live in.
Jan Lötvall, Editor-in-Chief - Clinical and Transla-
tional Allergy, Current EAACI President
Victoria Cardona, Managing Editor - Clinical and
Translational Allergy, Current EAACI Vice President
Communication and Membership
Author details
1University of Gothenburg, S-405 30 Gothenburg, Sweden.
2Hospital
Universitari Vall d’Hebron, Passeig de la Vall d’Hebron, 119-129, 08035
Barcelona, Spain.
Received: 8 June 2011 Accepted: 10 June 2011 Published: 10 June 2011
References
1. Scadding G, Hellings P, Alobid I, Bachert C, Fokkens W, Gerth van Wijk R,
Gevaert P, Guilemany J, Kalogjera L, Lund V, Mullol J, Passalacqua G,
Toskala E, van Drunen C: Diagnostic tools in rhinology. Clin Transl Allergy
2011, 1:2.
2. Woo CK, Bahna SL: Not all shellfish “allergy” is allergy! Clin Transl Allergy
2011, 1:3.
3. Chaudhary N, Marr KA: Impact of Aspergillus fumigatus in Allergic Airway
Diseases. Clin Transl Allergy 2011, 1:4.
4. Mattila P, Joenvaara S, Renkonen J, Toppila-Salmi S, Renkonen R: Allergy as
an epithelial barrier disease. Clin Transl Allergy 2011, 1:5.
5. BioMed Central open access waiver fund:[http://www.biomedcentral.com/
info/authors/oawaiverfund/].
doi:10.1186/2045-7022-1-1
Cite this article as: Lötvall and Cardona: Welcome to Clinical and
Translational Allergy. Clinical and Translational Allergy 2011 1:1.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lötvall and Cardona Clinical and Translational Allergy 2011, 1:1
http://www.ctajournal.com/content/1/1/1
Page 2 of 2